Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Optimization of Image Quality for Quantitative Multicontrast Atherosclerosis Characterization (qMATCH): Comparison between Transverse and Coronal Acquisitions

Hsu YC, Lu M, Llanes A, Keushkerian MJ, Nguyen KL, Johnson K, Altbach MI, Morris HD, DeMarco JK, Deshpande V, Mitsouras D, Saloner D, McNally[...]

Investments in Childhood Community Resources and Subsequent Adult Health Outcomes

La Charite J, Dudovitz R, Choi K, Chen K, Jackson NJ, Nuckols T, Sastry N, Schickedanz A, Wong MD, Zimmerman FJ. Investments in Childhood Community[...]

Short-term outcomes of laparoscopic hiatal hernia repair with consecutive transoral incisionless fundoplication (cTIF): a prospective multicenter cohort study

Kolb JM, Canto MI, Parker B, Murray M, Brewer Gutierrez OI, Sharaiha RZ, Samarasena J, Thosani NC, Abu-Dayyeh BK, Janu P, Chang KJ, Nguyen NT.[...]